NasdaqGS:SIEN

Stock Analysis Report

Executive Summary

Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States.

Rewards

Revenue is forecast to grow 22.05% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months



Snowflake Analysis

Excellent balance sheet with limited growth.


Similar Companies

Share Price & News

How has Sientra's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SIEN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.7%

SIEN

2.2%

US Medical Equipment

1.5%

US Market


1 Year Return

-41.4%

SIEN

22.1%

US Medical Equipment

20.1%

US Market

Return vs Industry: SIEN underperformed the US Medical Equipment industry which returned 22.1% over the past year.

Return vs Market: SIEN underperformed the US Market which returned 20.1% over the past year.


Shareholder returns

SIENIndustryMarket
7 Day-2.7%2.2%1.5%
30 Day-20.3%1.0%1.4%
90 Day-23.5%8.7%8.7%
1 Year-41.4%-41.4%23.0%22.1%22.7%20.1%
3 Year-32.6%-32.6%84.6%79.4%50.1%40.5%
5 Year-65.1%-65.1%117.1%94.4%73.1%54.1%

Price Volatility Vs. Market

How volatile is Sientra's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sientra undervalued compared to its fair value and its price relative to the market?

3.13x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SIEN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SIEN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SIEN is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: SIEN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SIEN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SIEN is good value based on its PB Ratio (3.1x) compared to the US Medical Equipment industry average (4x).


Next Steps

Future Growth

How is Sientra forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

29.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SIEN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SIEN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SIEN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SIEN's revenue (22% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: SIEN's revenue (22% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SIEN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Sientra performed over the past 5 years?

-36.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SIEN is currently unprofitable.

Growing Profit Margin: SIEN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SIEN is unprofitable, and losses have increased over the past 5 years at a rate of -36.7% per year.

Accelerating Growth: Unable to compare SIEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SIEN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (7.1%).


Return on Equity

High ROE: SIEN has a negative Return on Equity (-115.51%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Sientra's financial position?


Financial Position Analysis

Short Term Liabilities: SIEN's short term assets ($179.2M) exceed its short term liabilities ($64.1M).

Long Term Liabilities: SIEN's short term assets ($179.2M) exceed its long term liabilities ($59.5M).


Debt to Equity History and Analysis

Debt Level: SIEN's debt to equity ratio (47.2%) is considered high.

Reducing Debt: SIEN's debt to equity ratio has reduced from 113.2% to 47.2% over the past 5 years.


Balance Sheet

Inventory Level: SIEN has a high level of physical assets or inventory.

Debt Coverage by Assets: SIEN's debt is covered by short term assets (assets are 3.9x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SIEN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SIEN has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of -34.7% each year.


Next Steps

Dividend

What is Sientra's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate SIEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SIEN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SIEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SIEN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SIEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Jeff Nugent (72yo)

4.3yrs

Tenure

US$2,997,871

Compensation

Mr. Jeffrey M. Nugent, also known as Jeff, has been the Chairman and Chief Executive Officer at Sientra, Inc. since November 12, 2015. Mr. Nugent has been a Director of Sientra, Inc. since July 2014. He se ...


CEO Compensation Analysis

Compensation vs Market: Jeff's total compensation ($USD3.00M) is above average for companies of similar size in the US market ($USD1.68M).

Compensation vs Earnings: Jeff's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Jeffrey Nugent
Chairman & CEO4.3yrsUS$3.00m0.69% $2.1m
Paul Little
CFO, Senior VP & Treasurer1.5yrsUS$1.59m0.035% $106.1k
Charles Huiner
Consultant0.4yrsUS$1.29m0.14% $408.5k
Keith Sullivan
Director & Advisor to MiraDry Business2.5yrsUS$1.40m0.35% $1.1m
Deborah Bettencourt
Vice President of Customer Experience & Corporate Administration0yrsno datano data
Neil Bhalodkar
Senior Director of Investor Relations and Business Analytics1.3yrsno datano data
Oliver Bennett
General Counsel and VP of Compliance & Legal2.1yrsno datano data
Valerie Miller
VP & Corporate Controller1.9yrsno datano data

1.5yrs

Average Tenure

55yo

Average Age

Experienced Management: SIEN's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Jeffrey Nugent
Chairman & CEO4.3yrsUS$3.00m0.69% $2.1m
Keith Sullivan
Director & Advisor to MiraDry Business2.5yrsUS$1.40m0.35% $1.1m
Nicholas Simon
Lead Independent Director4.3yrsUS$197.51k0.076% $229.7k
Kevin O'Boyle
Independent Director5.6yrsUS$188.76k0.11% $328.0k
Philippe Schaison
Independent Director3yrsUS$296.26k0.089% $267.3k
Caroline Van Hove
Director0.08yrsno datano data
Mary Fisher
Independent Director1.1yrsno datano data

3.0yrs

Average Tenure

63yo

Average Age

Experienced Board: SIEN's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 53.5%.


Top Shareholders

Company Information

Sientra, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sientra, Inc.
  • Ticker: SIEN
  • Exchange: NasdaqGS
  • Founded: 2003
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$301.838m
  • Shares outstanding: 49.48m
  • Website: https://sientra.com

Number of Employees


Location

  • Sientra, Inc.
  • 420 South Fairview Avenue
  • Suite 200
  • Santa Barbara
  • California
  • 93117
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SIENNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 2014
S0ZDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2014

Biography

Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline filled breast implant sizers; and miraDry System, a non-surgical device for the permanent reduction of underarm sweat, odor, and hair of all colors. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/17 00:46
End of Day Share Price2020/02/14 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.